Design, Biologic Evaluation, and SAR of Novel Pseudo‐peptide Incorporating Benzheterocycles as HIV‐1 Protease Inhibitors

A series of novel HIV‐1 protease inhibitors based on the (hydroxyethylamino)‐sulfonamide isostere incorporating substituted phenyls and benzheterocycle derivatives bearing rich hydrogen bonding acceptors as P2 ligands were synthesized. Prolonged chain linking the benzhereocycle to the carbonyl group resulted in partial loss of binding affinities. Introduction of a small alkyl substituent with appropriate size to the ‐CH2‐ of P1‐P2 linkage as a side chain resulted in improved inhibitory potency, and in this study, isopropyl was the best side chain. Replacement of the isobutyl substituent at P1′group with phenyl substituent decreased the inhibitory potency. One of the most potent inhibitor, compound 23 showing high affinity to HIV‐1 protease with an IC50 value of 5 nm, also exhibited good anti‐SIV activity (EC50 = 0.8 μm) with low toxicity (TC50 > 100 μm). The flexible docking of inhibitor 23 to HIV‐1 protease active site rationalized the interactions with protease.

[1]  Arun K. Ghosh,et al.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. , 2007, Bioorganic & medicinal chemistry.

[2]  G. Klebe,et al.  Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization. , 2005, Journal of medicinal chemistry.

[3]  Erik De Clercq,et al.  HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. , 2004 .

[4]  H. Merzouk,et al.  The Synthesis of N‐Acyl‐2‐hydroxymethyl Aziridines of Biological Interest. , 2004 .

[5]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[6]  R. Pomerantz,et al.  Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.

[7]  Masahiro Wakao,et al.  Efficient method to prepare hydroxyethylamine-based aspartyl protease inhibitors with diverse P1 side chains , 2002 .

[8]  Chi‐Huey Wong,et al.  A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. , 2002, Chemistry & biology.

[9]  S. Rusconi,et al.  HIV-1 protease inhibitors in development , 2002, Expert opinion on investigational drugs.

[10]  Gang Pei,et al.  Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. , 2002, Journal of medicinal chemistry.

[11]  R. Hoffman,et al.  Highly Stereoselective Synthesis of an ti -N-Protected-a-Amino Epoxides , 2001 .

[12]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[13]  John P. Moore,et al.  New targets for inhibitors of HIV-1 replication , 2000, Nature Reviews Molecular Cell Biology.

[14]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.

[15]  Arthur J. Olson,et al.  Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants , 1999 .

[16]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[17]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[18]  M. H. Arief.  SYNTHESIS OF SOME SACCHARIN DERIVATIVES OF EXPECTED BIOLOGICAL ACTIVITY BASED ON N-(SACCHARINYL)-ACETIC ACID AZIDE , 1996 .

[19]  D. Cooper,et al.  HIV protease inhibitors , 1996, AIDS.

[20]  T. Meek,et al.  Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. , 1990, Biochemical and biophysical research communications.

[21]  H. Merritt,et al.  Synthetic Anticonvulsants. The Preparation and Properties of Some Benzoxazoles1 , 1945 .

[22]  Irene T Weber,et al.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. , 2008, Accounts of chemical research.

[23]  E. De Clercq,et al.  HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. , 2004, The international journal of biochemistry & cell biology.

[24]  Douglas D. Richman,et al.  HIV chemotherapy : AIDS , 2001 .

[25]  Douglas D. Richman,et al.  HIV chemotherapy , 2001, Nature.

[26]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[27]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .